Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PGRN: Cholesterol and Pharmacogenetics Study (CAP)

ABSTRACT: PGRN: Cholesterol and Pharmacogenetics Study (CAP)

PROVIDER: PRJNA156877 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Homo sapiens

Project description:PGRN: Cholesterol and Pharmacogenetics Study (CAP)

| PRJNA156879 | ENA

Cholesterol and Pharmacogenetics (CAP) Study

Project description:The Cholesterol and Pharmacogenetics Study was a 6-week open label, non-randomized study of 40mg/day simvastatin treatment in 944 African-American and Caucasian men and women. Plasma lipid and lipoprotein were measured on two occasions prior to treatment and at 4 and 6 weeks of treatment. The study was designed to test for genetic associations to baseline measurements and changes in response to simvastatin treatment. Whole genome genotyping was performed on 592 Caucasians CAP study participants in two stages. In Stage 1, 304 were genotyped for 314,621 SNPs to tag for common genomic variation. In Stage 2, 290 subjects were genotyped, which included 280 subjects genotyped for 620,901 SNPs. Two samples were excluded due to gender discrepancies.

| phs000481.v1.p1 | EGA

Cholesterol and Pharmacogenetics (CAP) Study

Project description:The Cholesterol and Pharmacogenetics Study was a 6-week open label, non-randomized study of 40mg/day simvastatin treatment in 335 African-American and 609 Caucasian (944 total) men and women. Plasma lipids and lipoproteins were measured on two occasions prior to treatment and at 4 and 6 weeks of treatment. The study was designed to test for genetic associations with baseline measurements and changes in response to simvastatin treatment. Whole genome genotyping was performed on 592 Caucasian CAP study participants in two stages. In Stage 1, 304 were genotyped for 314,621 SNPs to tag for common genomic variation. In Stage 2, 290 participants were genotyped, including 280 who were genotyped for 620,901 SNPs. Two samples were excluded due to gender discrepancies. PolyA-selected strand-specific RNA-seq libraries were generated from lymphoblastoid cell lines (LCLs) derived from 104 Caucasian and 53 African American CAP participants. The LCLs were exposed to sham buffer (control) or 2 uM activated simvastatin for 24 hours, producing a total of 314 100/101 bp paired end RNA-seq libraries sequenced on Illumina HiSeq 2000 machines.

| phs000481 | dbGaP

PGRN-RIKEN Mayo-NSABP Prevention Study

Project description:PGRN-RIKEN Mayo-NSABP Prevention Study

| PRJNA75693 | ENA

Simvastatin treated Lymphoblastoid Cell lines from Cholesterol and Pharmacogenomics (CAP) Trial

Project description:Statins reduce cardiovascular disease risk by lowering plasma low density lipoprotein (LDL)-cholesterol. To identify novel pathways that modulate statin response, we assessed the influence of simvastatin exposure on expression quantitative trait locus (eQTL) associations across the genome in 480 lymphoblastoid cell lines (LCLs). Cell lines were derived blood samples collected ant entry visit from participants in the Cholesterol and Pharmacogenomics (CAP) trial, who underwent a 6 week 40mg/day simvastatin trial. We identified 4590 cis-eQTLS that were independent of treatment status (FDR=1%) and six cis-eQTLS for which there was evidence of an interaction with treatment (FDR=20%). Genotypes and Phenotypes derived from these indivudals are available through dbGaP (Accession Number). eQTL results are available at: http://eqtl.uchicago.edu/cgi=bin/gbrowse/eqtl/ Dataset consists of 960 expression beadarrays (Illumina HumanRef-8v3) representing paired samples derived from 24-hour exposures of 480 lymphoblastoid cell lines (LCLs) to 2 micromolar simvastatin acid or control buffer.

2012-06-30 | E-GEOD-36868 | biostudies-arrayexpress

Simvastatin treated Lymphoblastoid Cell lines from Cholesterol and Pharmacogenomics (CAP) Trial

2012-07-01 | GSE36868 | GEO

PGRN: Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)

Project description:PGRN: Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)

| PRJNA80255 | ENA

PGRN-RIKEN:Genome-Wide Association Study of Drug-Induced Long-QT Syndrome

Project description:PGRN-RIKEN:Genome-Wide Association Study of Drug-Induced Long-QT Syndrome

| PRJNA75677 | ENA

PGRN-RIKEN Mayo Breast Cancer

Project description:PGRN-RIKEN Mayo Breast Cancer

| PRJNA75545 | ENA

Next-generation sequencing analysis of wild-type and PGRN-/- mouse neutrophils challenged with Candida albicans [RNA-seq]

Project description:To investigate the effect of Progranulin on neutrophils phagocytosis and killing of Candida albicans, we designed RNA-Seq analysis of wild-type and PGRN-/- neutrophils challenged with Candida albicans in vitro at one time point.

2022-09-13 | GSE201166 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data